Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents : The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry

Access this Article

Search this Article

Author(s)

    • HAHN Joo-Yong
    • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    • SONG Young Bin
    • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    • CHOI Jin-Ho
    • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    • CHOI Sung-Hyuk
    • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    • LEE Sang Hoon
    • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    • GWON Hyeon-Cheol
    • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Abstract

<b><i>Background:</i></b> The optimal duration of dual antiplatelet therapy remains controversial. <b><i>Methods and Results:</i></b> Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200mg+clopidogrel 75mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48-1.67) after adjustment for the propensity score. <b><i>Conclusions:</i></b> Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients. (<i>Circ J</i> 2010; <b>74:</b> 2314-2321)<br>

Journal

  • Circulation Journal

    Circulation Journal 74(11), 2314-2321, 2010-10-25

    The Japanese Circulation Society

References:  27

Cited by:  1

Codes

  • NII Article ID (NAID)
    10026972637
  • NII NACSIS-CAT ID (NCID)
    AA11591968
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    13469843
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top